JP2022520080A5 - - Google Patents
Info
- Publication number
- JP2022520080A5 JP2022520080A5 JP2021546888A JP2021546888A JP2022520080A5 JP 2022520080 A5 JP2022520080 A5 JP 2022520080A5 JP 2021546888 A JP2021546888 A JP 2021546888A JP 2021546888 A JP2021546888 A JP 2021546888A JP 2022520080 A5 JP2022520080 A5 JP 2022520080A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- gene
- adenosine
- base editor
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024193416A JP2025032080A (ja) | 2019-02-13 | 2024-11-05 | 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法 |
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805271P | 2019-02-13 | 2019-02-13 | |
| US62/805,271 | 2019-02-13 | ||
| US201962850919P | 2019-05-21 | 2019-05-21 | |
| US62/850,919 | 2019-05-21 | ||
| US201962852224P | 2019-05-23 | 2019-05-23 | |
| US201962852228P | 2019-05-23 | 2019-05-23 | |
| US62/852,228 | 2019-05-23 | ||
| US62/852,224 | 2019-05-23 | ||
| US201962873138P | 2019-07-11 | 2019-07-11 | |
| US62/873,138 | 2019-07-11 | ||
| US201962888867P | 2019-08-19 | 2019-08-19 | |
| US62/888,867 | 2019-08-19 | ||
| US201962931722P | 2019-11-06 | 2019-11-06 | |
| US62/931,722 | 2019-11-06 | ||
| US201962941569P | 2019-11-27 | 2019-11-27 | |
| US62/941,569 | 2019-11-27 | ||
| US202062966526P | 2020-01-27 | 2020-01-27 | |
| US62/966,526 | 2020-01-27 | ||
| PCT/US2020/018073 WO2020168051A1 (en) | 2019-02-13 | 2020-02-13 | Methods of editing a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193416A Division JP2025032080A (ja) | 2019-02-13 | 2024-11-05 | 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022520080A JP2022520080A (ja) | 2022-03-28 |
| JP2022520080A5 true JP2022520080A5 (https=) | 2023-02-21 |
| JP7586601B2 JP7586601B2 (ja) | 2024-11-19 |
Family
ID=72045106
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546888A Active JP7586601B2 (ja) | 2019-02-13 | 2020-02-13 | 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法 |
| JP2024193416A Pending JP2025032080A (ja) | 2019-02-13 | 2024-11-05 | 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193416A Pending JP2025032080A (ja) | 2019-02-13 | 2024-11-05 | 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230140953A1 (https=) |
| EP (1) | EP3924484A4 (https=) |
| JP (2) | JP7586601B2 (https=) |
| KR (1) | KR20210127206A (https=) |
| CN (2) | CN114040970B (https=) |
| AU (1) | AU2020223306A1 (https=) |
| CA (1) | CA3128876A1 (https=) |
| WO (1) | WO2020168051A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019178427A1 (en) | 2018-03-14 | 2019-09-19 | Arbor Biotechnologies, Inc. | Novel crispr dna targeting enzymes and systems |
| AU2019265019B2 (en) | 2018-05-11 | 2025-11-06 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| WO2019222555A1 (en) | 2018-05-16 | 2019-11-21 | Arbor Biotechnologies, Inc. | Novel crispr-associated systems and components |
| EP3847254A4 (en) | 2018-09-07 | 2022-08-10 | Beam Therapeutics Inc. | COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM |
| WO2020051562A2 (en) | 2018-09-07 | 2020-03-12 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| AU2020215730A1 (en) | 2019-01-31 | 2021-07-29 | Beam Therapeutics Inc. | Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editors |
| CA3128755C (en) | 2019-02-13 | 2024-06-04 | Beam Therapeutics Inc. | Compositions and methods for treating hemoglobinopathies |
| CN120174005A (zh) | 2019-02-13 | 2025-06-20 | 比姆医疗股份有限公司 | 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞 |
| EP3956449B1 (en) | 2019-04-15 | 2026-02-25 | EdiGene Therapeutics (Beijing) Inc. | Methods and compositions for editing rnas |
| EP3997229A4 (en) | 2019-07-12 | 2024-07-03 | Peking University | TARGETED RNA EDITING BY HARNESSING ENDOGENOUS ADAR USING MODIFIED RNA |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| KR20220119129A (ko) * | 2019-12-30 | 2022-08-26 | 에디진 테라퓨틱스 (베이징) 인크. | Leaper 기술에 기반한 mps ih 치료 방법 및 조성물 |
| WO2021163587A1 (en) * | 2020-02-13 | 2021-08-19 | Beam Therapeutics Inc. | Compositions and methods for engraftment of base edited cells |
| US20230340486A1 (en) * | 2020-07-27 | 2023-10-26 | The Children’S Hospital Of Philadelphia | In utero and postnatal gene editing and therapy for treatment of monogenic diseases, including mucopolysaccharidosis type 1h and other disorders |
| CA3196831A1 (en) | 2020-09-25 | 2022-03-31 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| US20240110177A1 (en) * | 2020-10-21 | 2024-04-04 | The Board Of Trustees Of The Leland Stanford Junior University | A screening platform for adar-recruiting guide rnas |
| KR20240007651A (ko) * | 2021-04-16 | 2024-01-16 | 빔 테라퓨틱스, 인크. | 간세포의 유전적 변형 |
| AU2022272250A1 (en) * | 2021-05-14 | 2023-11-30 | Beam Therapeutics Inc. | Compositions and methods for treating transthyretin amyloidosis |
| WO2022246266A1 (en) * | 2021-05-21 | 2022-11-24 | Beam Therapeutics Inc. | Base editing of transthyretin gene |
| EP4426821A1 (en) * | 2021-11-02 | 2024-09-11 | University of Massachusetts | Nme2cas9 inlaid domain fusion proteins |
| EP4441219A2 (en) * | 2021-12-01 | 2024-10-09 | Shape Therapeutics Inc. | Engineered guide rnas and polynucleotides for rna editing targeting lrrk2 |
| WO2023169454A1 (zh) * | 2022-03-08 | 2023-09-14 | 中国科学院遗传与发育生物学研究所 | 腺嘌呤脱氨酶及其在碱基编辑中的用途 |
| CN114686456B (zh) * | 2022-05-10 | 2023-02-17 | 中山大学 | 基于双分子脱氨酶互补的碱基编辑系统及其应用 |
| JP2025530183A (ja) * | 2022-09-08 | 2025-09-11 | ザ ユニヴァーシティ コート オブ ザ ユニヴァーシティ オブ エディンバラ | レット症候群治療法 |
| WO2024230760A1 (zh) * | 2023-05-09 | 2024-11-14 | 北京齐禾生科生物科技有限公司 | 一种可作用于dna的腺苷脱氨酶及其应用 |
| WO2024233941A1 (en) * | 2023-05-11 | 2024-11-14 | Massachusetts Eye And Ear Infirmary | Base editing approaches to treat abca4-associated stargardt disease |
| WO2024238623A1 (en) * | 2023-05-15 | 2024-11-21 | University Of Georgia Research Foundation, Inc. | Doubly constrained peptides as allosteric inhibitors of leucine rich repeat kinase 2 |
| CN117965505A (zh) * | 2023-06-28 | 2024-05-03 | 微光基因(苏州)有限公司 | 工程化的腺苷脱氨酶及碱基编辑器 |
| CN120536418A (zh) * | 2024-02-26 | 2025-08-26 | 尧唐(上海)生物科技有限公司 | 一种脱氨酶变体、包含其的碱基编辑器及其应用 |
| WO2025184515A1 (en) * | 2024-02-29 | 2025-09-04 | Vesigen, Inc. | Arrdc1-mediated microvesicle-based delivery of therapeutic agents to cells and tissues of the eye |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012004778A1 (en) * | 2010-07-09 | 2012-01-12 | Ecole Polytechnique Federale De Lausanne (Epfl) | Method for in-vitro monitoring of neuronal disorders and use thereof |
| BR112017007765B1 (pt) * | 2014-10-14 | 2023-10-03 | Halozyme, Inc | Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo |
| CN110214183A (zh) * | 2016-08-03 | 2019-09-06 | 哈佛大学的校长及成员们 | 腺苷核碱基编辑器及其用途 |
| KR102622411B1 (ko) * | 2016-10-14 | 2024-01-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| US11866697B2 (en) * | 2017-05-18 | 2024-01-09 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| KR102761791B1 (ko) * | 2017-06-26 | 2025-02-05 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 crispr/cas-아데닌 데아미나아제 기반 조성물, 시스템 및 방법 |
| CN109306361B (zh) * | 2018-02-11 | 2022-06-28 | 华东师范大学 | 一种新的a/t到g/c碱基定点转换的基因编辑系统 |
| CN109295186B (zh) * | 2018-09-30 | 2023-10-03 | 中山大学 | 一种基于全基因组测序检测腺嘌呤单碱基编辑系统脱靶效应的方法及其在基因编辑中的应用 |
-
2020
- 2020-02-13 US US17/430,672 patent/US20230140953A1/en active Pending
- 2020-02-13 EP EP20756724.9A patent/EP3924484A4/en active Pending
- 2020-02-13 JP JP2021546888A patent/JP7586601B2/ja active Active
- 2020-02-13 CA CA3128876A patent/CA3128876A1/en active Pending
- 2020-02-13 WO PCT/US2020/018073 patent/WO2020168051A1/en not_active Ceased
- 2020-02-13 CN CN202080028186.5A patent/CN114040970B/zh active Active
- 2020-02-13 KR KR1020217029268A patent/KR20210127206A/ko active Pending
- 2020-02-13 CN CN202411269394.0A patent/CN119280261A/zh active Pending
- 2020-02-13 AU AU2020223306A patent/AU2020223306A1/en active Pending
-
2024
- 2024-11-05 JP JP2024193416A patent/JP2025032080A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022520080A5 (https=) | ||
| JP2025032080A5 (https=) | ||
| Tsai et al. | Addition of m6A to SV40 late mRNAs enhances viral structural gene expression and replication | |
| Hom et al. | Deep mutational scan of the highly conserved influenza A virus M1 matrix protein reveals substantial intrinsic mutational tolerance | |
| Meijer et al. | φ29 family of phages | |
| Feng et al. | Substrate specificity of human protein arginine methyltransferase 7 (PRMT7): the importance of acidic residues in the double E loop | |
| BR112020006786A2 (pt) | composições e métodos para editar rna | |
| JP2022545950A5 (https=) | ||
| JPH05506997A (ja) | オリゴヌクレオチドによるインフルエンザウィルス複製の阻止 | |
| JP2010528617A5 (ja) | リボスイッチならびにリボスイッチを使用するためのおよびリボスイッチと共に使用するための方法および組成物 | |
| WO2016069591A2 (en) | Compositions, methods and use of synthetic lethal screening | |
| Florian et al. | Characterization of the anti‐HBV activity of HLP1–23, a human lactoferrin‐derived peptide | |
| Ren et al. | Current progress on host antiviral factor IFITMs | |
| Huang et al. | Involvement of the zinc-binding capacity of Sendai virus V protein in viral pathogenesis | |
| CN121079310A (zh) | 用于治疗与cdkl5缺乏相关的病症的组合物及方法 | |
| Jordan-Paiz et al. | Impact of synonymous genome recoding on the HIV life cycle | |
| Wen et al. | Current progress on innate immune evasion mediated by Npro protein of pestiviruses | |
| Schotte et al. | Characterization of poliovirus neutralization escape mutants of single-domain antibody fragments (VHHs) | |
| KR20110049749A (ko) | 양성-센스 단일-사슬 ｒｎａ 바이러스로의 감염을 예방 또는 치료하기 위한 대형 인간 2´,5´-올리고아데닐레이트 합성효소 ｏａｓ3 | |
| EP4008343A2 (en) | Methods and compositions related to increased viral production | |
| Tian et al. | AntiV‐SGN: a universal antiviral strategy to combat both RNA and DNA viruses by destroying their nucleic acids without sequence limitation | |
| Baquero-Perez et al. | From A to m6A: The Emerging Viral Epitranscriptome. Viruses 2021, 13, 1049 | |
| CN110214013A (zh) | 抗病毒剂及治疗病毒感染的方法 | |
| Roos | Pathogenesis of Theiler’s murine encephalomyelitis virus‐induced disease | |
| EP3481419A1 (en) | Rna virus vectors carrying dai and ripk3 |